



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Daniel Caput et al.

CERTIFICATE UNDER 37 C.F.R. 1.8(a)

Serial No.: 09/077,817

I hereby certify that this correspondence is being deposited on the date indicated below with the United States Postal Service addressed to:

Filed: September 14, 1998

Commissioner for Patents
Washington, DC 20231

Group Art Unit: 1646

Examiner: Basi, N.

For: Purified Polypeptides Having IL-13
Receptor Activity

Name

Date

Geraldine D. Ska...
December 19, 2002

30/3
M.G.J.
1/27/03
RECEIVED
JAN 02 2003
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

AMENDMENT

In response to the Office Action mailed July 2, 2002 (Paper No. 28), please amend the above-identified application as follows:

In the specification:

Please replace the Sequence Listing following page 36 with the corrected Sequence Listing submitted herewith on replacement pages 37-47, and please replace the computer readable copy of the sequence listing with the computer readable copy submitted herewith.

In the claims:

Please amend claims 72, 78-80, 83, 87, and 111-113 to read as follows:

72. (Amended) An isolated IL-13bc (IL13R β) protein comprising an amino acid sequence selected from the group consisting of:

- 32
- (a) the amino acid sequence of SEQ ID NO: 2;
 - (b) the amino acid sequence of SEQ ID NO: 2 from amino acids 26 to 341;
 - (c) the amino acid sequence of SEQ ID NO: 2 from amino acids 363 to 380; and
 - (d) fragments of (a)-(c) which bind IL-13 or a biologically active fragment thereof.

33
78. (Amended) A protein produced according to a process comprising: